Compare TMDX & MGNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMDX | MGNI |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | N/A | 514 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.7B |
| IPO Year | 2019 | 2014 |
| Metric | TMDX | MGNI |
|---|---|---|
| Price | $83.30 | $23.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $148.22 | $25.22 |
| AVG Volume (30 Days) | 847.3K | ★ 2.8M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 382.18 | ★ 493.75 |
| EPS | ★ 0.61 | 0.16 |
| Revenue | ★ $605,494,000.00 | $156,414,000.00 |
| Revenue This Year | $24.25 | $6.28 |
| Revenue Next Year | $18.75 | $9.76 |
| P/E Ratio | ★ $144.97 | $148.13 |
| Revenue Growth | ★ 37.13 | 25.45 |
| 52 Week Low | $60.11 | $10.82 |
| 52 Week High | $156.00 | $26.19 |
| Indicator | TMDX | MGNI |
|---|---|---|
| Relative Strength Index (RSI) | 45.40 | 57.09 |
| Support Level | $66.64 | $17.50 |
| Resistance Level | $95.18 | $25.41 |
| Average True Range (ATR) | 3.49 | 0.75 |
| MACD | -0.96 | -0.24 |
| Stochastic Oscillator | 4.56 | 14.41 |
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Magnite is a supply-side advertising platform that provides technology and yield management solutions to content publishers, enabling them to monetize their digital advertising inventory. Magnite receives a percentage of all advertising inventory that it sells. 43% of Magnite's revenue is derived from connected television, or CTV, streaming platforms, 40% from mobile applications, and the remainder from general websites. Beyond the typical monetization responsibilities inherent to an SSP, Magnite also provides upstream advertising servers to CTV publishers, allowing them to have granular control over direct-sold, programmatic guaranteed, and open-auction logic. Magnite competes with other independent SSPs, supply path optimization solutions, and closed ecosystems like Meta.